The Kolff program aims to support talented postdoctoral / physician-researchers in the field of Nephrology. This prestigious Kolff grant allows Rutger to perform a three-year research project into the topic of idiopathic nephrotic syndrome, a group of rare kidney diseases.Customised treatment for patients with idiopathic nephrotic syndrome
Rutger Maas, department of Nephrology, will use his grant to develop improved methods to predict therapeutic efficacy of immunosuppressive drugs in patient with the idiopathic nephrotic syndrome.
Immunosuppressive treatment including high-dose prednisone is currently the only effective treatment for these diseases. However, responses are highly variable and the drugs often cause serious side-effects. The project aims to accurately predict treatment response at an earlier stage in the disease, thereby enabling personalized treatment.
The award of the grant to the Radboudumc underlines the strength of the Renal Disorders theme in Nijmegen.
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more
Association of gestational weight gain with adverse maternal and infant outcomes13 May 2019
An individual participant meta-analysis published in JAMA showed that pregnancy BMI is related stronger to maternal and infant complications than to gestational weight gain. The PRIDE Study, with coauthors Marleen van Gelder and Nel Roeleveld, was one of the participating cohorts.read more